Wednesday, July 8, 2026

Patent intelligence · US

US 9387205

Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

granted A61KA61K31/473A61K31/4985A61K31/501
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 10
Applicant portfolio 1,436
Patent details — US 9387205
Jurisdiction
US
Status
granted
Grant date
Jul 12, 2016
Expiration
Jul 7, 2036
Applicant
TAKEDA GMBH
Claims
5
CPC classes
A61K, A61K31/473, A61K31/4985, A61K31/501
View on Google Patents ↗

Quick answer

US 9387205 (Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors) is held by TAKEDA GMBH. Status: granted. Granted Jul 12, 2016. Expires Jul 7, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
TAKEDA GMBH
Grant date
Expiration
Claims
5
CPC classes
A61K, A61K31/473, A61K31/4985, A61K31/501, A61K31/506, A61K31/5377

More from TAKEDA GMBH

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 9387205?

US 9387205 (Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors) is held by TAKEDA GMBH. Status: granted. Granted Jul 12, 2016. Expires Jul 7, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9387205?

TAKEDA GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 9387205 expire?

Our index shows an expiration date of Jul 7, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.